Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program. Issue 2 (28th January 2023)

• Record Type: Journal Article
• Authors: Mulligan, Stephen P.; Opat, Stephen; Cheah, Chan Y.; Kuss, Bryone; Hertzberg, Mark; Marlton, Paula; Poplar, Sarah; Puig, Andrea; McGeachie, Marija; Weinkove, Robert; Tam, Constantine S.
• Is Part Of: Leukemia & lymphoma. Volume 64:Issue 2(2023)
• Page Start: 312
• Page End: 318
• Publication Date: 2023-01-28
• Subjects: Ibrutinib -- real-world -- mantle cell leukemia -- chronic lymphocytic leukemia; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2148220
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase indicated for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The Named Patient Program in Australia and New Zealand (ANZ NPP) provided access to ibrutinib treatment to 1126 R/R CLL/SLL and 330 R/R MCL patients, prior to Pharmaceutical Benefits Scheme listing. This study aimed to assess the duration of treatment for the ANZ NPP patients, as an indicator of efficacy and tolerability of ibrutinib in the real world. Based on the NPP data, ibrutinib provided a median of 47 months clinical benefit for participants with CLL/SLL and 14 months clinical benefit for those with MCL; outcomes that are consistent with the clinical trial results and further support the well-established efficacy and safety profile of ibrutinib in the real world.